Table 3.
Disease Characteristics and Biomarker Results for Subjects With Endoscopic Inactive and Endoscopic Active Crohn’s Disease
| Endoscopic Inactive (n = 19) | Endoscopic Active (n = 102)a | |
|---|---|---|
| Mean age at endoscopy (SD), y | 16 (4) | 14 (4) |
| Mean age at diagnosis (SD), y | 12 (5) | 12 (4) |
| Median duration with Crohn’s (range), y | 4.2 (0.5–14) | 0 (0–16)b |
| Female, % | 5 (26%) | 35 (34%) |
| White race, % | 18 (95%) | 92 (90%) |
| Crohn’s location | ||
| Ileal only (L1) | 2 | 11 |
| Colon only (L2) | 6 | 22 |
| Ileocolonic (L3) | 11 | 69 |
| Crohn’s behavior | ||
| Inflammatory (B1) | 14 | 77 |
| Stricturing (B2) | 4 | 14 |
| Penetrating (B3) | 1 | 10 |
| Both (B2B3) | 0 | 1 |
| Perianal | 3 | 15 |
| Prior surgery, % | 3 (16%) | 5 (5%) |
| Medications, % | ||
| Prednisone | 1 (6%) | 11 (26%) |
| 6-mercaptopurine or methotrexate | 7 (39%) | 19 (45%) |
| Anti-TNF without IMM | 9 (50%) | 18 (43%) |
| Anti-TNF and IMM | 2 (11%) | 3 (7%) |
| Vedolizumab or ustekinumab | 0 | 3 (7%) |
| 5-aminosalicylate only | 2 (11%) | 3 (7%) |
| None | 1 | 60 |
| SES-CD, median (range) | 0 (0–2) | 12 (3–34)b |
| Neutrophil CD64 index, median (range) | 0.61 (0.3–1.2) | 1.3 (0.4–6)b |
| Soluble CD64, median (range), ng/mL | 38 (20–62) | 60 (15–179)b |
| Neutrophil CD64 activity ratio, median (range) | 3.6 (2.3–5.3) | 6.4 (2.2–32)b |
| C-reactive protein, median (range), mg/dL | 0.28 (0.28–0.49) | 1.6 (0.28–14)b |
| Fecal calprotectin, median (range), μg/g | 37 (15–1132) | 712 (55–1251)b |
aEndoscopic active includes 60 new-onset Crohn’s and 42 established Crohn’s. Medication percentage (%) based on those subjects receiving therapy at time of endoscopy.
b P < 0.001.
IMM = immunomodulator; SES-CD = Simple Endoscopic Score-Crohn’s disease.